Market Exclusive

Analyst Activity – BMO Capital Markets Reiterates Buy on bluebird bio (NASDAQ:BLUE)

Analyst Ratings For bluebird bio (NASDAQ:BLUE)

Today, BMO Capital Markets reiterated its Buy rating on bluebird bio (NASDAQ:BLUE) with a price target of $108.00.

There are 2 sell ratings, 5 hold ratings, 11 buy ratings on the stock.

The current consensus rating on bluebird bio (NASDAQ:BLUE) is Buy (Score: 2.50) with a consensus target price of $99.45 per share, a potential 6.48% upside.

Some recent analyst ratings include


Recent Trading Activity for bluebird bio (NASDAQ:BLUE)
Shares of bluebird bio closed the previous trading session at 93.40 up +2.55 2.81% with 943,427 shares trading hands.

Exit mobile version